Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 1, 2003, Pages 11-20

  Matheson, Stephanie L ^a   McNamee, James P ^b   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

Cell cycle perturbation; DNA damage; O6 alkylguanine DNA alkyltransferase (AGT); Receptor type specificity; Signal transduction

Indexed keywords

DNA; DRUG ANALOG; DRUG METABOLITE; INSULIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; PROTEIN KINASE P60; SMA 41; SMA 52; TEMOZOLOMIDE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL SURVIVAL; COMET ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ALKYLATION; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG ACTIVITY; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; DNA DAMAGE; EPIDERMAL GROWTH FACTOR; HUMANS; MICE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0037220070     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0525-4     Document Type: Article

References (25)

1. Matheson S, McNamee J, Jean-Claude BJ (2001) Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumour targeting strategy. J Pharmacol Exp Ther 296:832
2. Manning HW, Cameron LM, LaFrance RJ, Vaughan K, Rajaman R (1985) Triazene metabolism. V. Chemical and biological properties of N,N-bis-[1-aryl-3-methyltriazen-3-yl)-methyl]-methylamines: Potential prodrugs for the cytotoxic monomethyltriazenes. Anticancer Drug Des 1:37
3. Cameron LM, LaFrance RJ, Hemens CM, Vaughan K, Rajaraman R, Chubb DC, Goddard PM (1985) Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: Potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC. Anticancer Drug Des 1:27
4. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney HS, Boyd MR (1990) New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 82:1107
5. Moyer JD, Barbacci EG, Iwata K, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MJ, Neveu M, Pollak VA, Pustilnik LR, Reynolds MM, Sloan D, Teleman A, Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838
6. McNamee JP, Mclean JR, Ferrrotto CL, Bellier PV (2000) Comet assay: Rapid processing of multiple samples. Mutat Res 466:63
7. Xinmei C, Yeung TK, Wang Z (2000) Enhanced drug resistance in cells coexpressing erb2 with EGF receptor or erb3. Biochem Biophys Res Commun 277:757
8. Jean-Claude BJ, Mustafa A, Damian Z, De Marte J, Yen R, Chan TH, Leyland-Jones B (1998) Comparative studies between the effects of mitozolomide and two novel tetrazepinones PYRCL and QUINCL on NIH:OVCAR-3 cells. Cancer Chemother Pharmacol 42:59
9. Erba E, Pepe S, Ubezio P, Lorico A, Morasca L, Mangioni C, Landoni F, D'Incalci M (1986) Mitozolomide activity on human cancer cells in vitro. Br J Cancer 54:925
10. Bast RCJ, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuk A (1998) Coex-pression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17:313
11. Ilekis JV, Conner JP, Prins GS, Ferrer K, Niederberger C, Scoccia B (1997) Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66:250
12. Lamharzi N, Halmos G, Armatis P, Schally AV (1998) Expression of mRNA for luteinizing hormone-releasing receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 12:671
13. Nikura H, Sasano H, Sato S, Yajima A (1997) Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16:60
14. Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP (1993) Depletion of O-6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 66:1299
15. Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR (1996) Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2:735
16. Fairbairn LJ, Watson AJ, Rafferty JA, Elder RH, Margison GP (1995) O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol 23:112
17. 6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32:59
18. Wedge SR, Porteous JK, Newlands ES (1996) Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: A comparative study in vitro. Br J Cancer 73:482
19. Hengstler JG, Lange J, Kett A, Gornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B (1999) Contribution of c-erB-2 and topoisomerase II alpha to chemoresistance in ovarian cancer. Cancer Res 59:3206
20. Modjtahedi H, Dean C (1998) The receptor for EGF and its ligands: Expression, prognostic value and target for tumour therapy. Int J Oncol 4:277-296
21. Brader KR, Wolf JK, Chakrabarty S, Price JE (1998) Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncology 5:1269
22. Kaina B, Haas S, Kappes H (1997) A general role for c-fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res 57:2721
23. Lanzi C, Pensa T, Cassinis M, Corti C, Gambetta AR, Pratesi G, Menta E, Ardini E, Zagon IS (1997) A cell and mechanism-based approach for the selection of EGF receptor inhibitors. Anticancer Drug Des 12:515
24. Bishop PC, Myers T, Fry DW, Liu ETL, Bagoskonny M, Bates S (2002) Differential sensitivity of cancer cells to inhibitors of epidermal growth factor family. Oncogene 21:119
25. He H, Levitzki A, Zhu H, Walker G, Burgess A, Maruta H (2001) Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem 276:26741